1232423-55-0

Basic information

• Product Name: tert-butyl N-(5-bromo-3-ethynylpyrazin-2-yl)-N-[(tert-butoxy)carbonyl]carbamate
• Synonyms: tert-butyl N-(5-bromo-3-ethynylpyrazin-2-yl)-N-[(tert-butoxy)carbonyl]carbamate;Imidodicarbonic acid, 2-(5-bromo-3-ethynyl-2-pyrazinyl)-, 1,3-bis(1,1-dimethylethyl) ester;ditert-butyl 5-bromo-3-ethynylpyrazin-2-ylcarbamate;EOS-61576
• CAS NO: 1232423-55-0
• Molecular Formula: C₁₆H₂₀BrN₃O₄
• Molecular Weight: 398.26
• Mol File: 1232423-55-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl N-(5-bromo-3-ethynylpyrazin-2-yl)-N-[(tert-butoxy)carbonyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-(5-bromo-3-ethynylpyrazin-2-yl)-N-[(tert-butoxy)carbonyl]carbamate(1232423-55-0)
• EPA Substance Registry System: tert-butyl N-(5-bromo-3-ethynylpyrazin-2-yl)-N-[(tert-butoxy)carbonyl]carbamate(1232423-55-0)

Safety Data

• Hazardous Substances Data: 1232423-55-0(Hazardous Substances Data)

Upstream product

• 1232423-98-1 tert-butyl N-(3-ethynyl-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-yl)N-tertbutoxycarbonyl-carbamate ? 
• 1428935-59-4 C₉H₁₂BrN₃Si*C₇H₈O₃S 
• 1402390-93-5 tert-butyl N-[5-bromo-3-(2-triisopropylsilylethynyl)pyrazin-2-yl]-N-(tert-butoxycarbonyl)carbamate 
• 1225062-32-7 tert-butyl N-tert-butoxycarbonyl-N-[5-bromo-3-((trimethylsilyl)ethyynyl)pyrazin-2-yl]carbamate 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 

Downstream Products

• 1349734-88-8 tert-butyl N-[5-bromo-3-[3-(p-tolyl)isoxazol-5-yl]pyrazin-2-yl]-N-tert-butoxycarbonylcarbamate 
• 1428935-02-7 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-(((tetrahydro-2H-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine 
• 1428935-58-3 tert-butyl tert-butoxycarbonyl(3-(3-(4-(((tert-butoxycarbonyl)(tetrahydro-2H-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)-5-(4-(isopropylsulfonyl)phenyl)pyrazin-2-yl)carbamate 
• 1429233-26-0 tert-butyl N-[[4-[5-[3-[bis(tert-butoxycarbonyl)amino]-6-[4-[1,2,2,2-tetradeuterio-1-(trideuteriomethyl)ethyl]sulfonylphenyl]pyrazin-2-yl]isoxazol-3-yl]phenyl]methyl]-N-tetrahydropyran-4-yl-carbamate 
• 1349734-97-9 5-bromo-3-(3-(4-(chloromethyl)phenyl)isoxazol-5-yl)pyrazin-2-amine 
• 1402390-91-3 tert-butyl (5-bromo-3-(3-(4-(((tert-butoxycarbonyl)(tetrahydro-2H-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)(tert-butoxycarbonyl)carbamate 
• 1428935-55-0 C₃₉H₄₉N₅O₉S 
• 1432755-69-5 tert-butyl 3-((4-(5-((tert-butoxycarbonyl)amino)-6-(3-phenylisoxazol-5-yl)pyrazin-2-yl)phenyl)sulfonyl)piperidine-1-carboxylate 
• 1232425-40-9 tert-butyl (5-bromo-3-(3-phenylisoxazol-5-yl)pyrazin-2-yl)-N-tert-butoxycarbonyl-carbamate 
• 1432755-71-9 tert-butyl 3-[4-[5-[bis(tert-butoxycarbonyl)amino]-6-ethynyl-pyrazin-2-yl]phenyl]sulfonylpiperidine-1-carboxylate 
• 1349734-86-6 di-tert-butyl (5-bromo-3-(3-(4-(chloromethyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)carbamate 
• 1402390-41-3 tert-butyl N-[5-bromo-3-[3-[4-[1-(tert-butoxycarbonylamino)-2-fluoroethyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]-N-(tert-butoxycarbonyl)carbamate 
• 1402389-48-3 2-(4-(5-amino-6-(3-(4-(((tetrahydro-2H-pyran-4-yl)amino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)pyridin-2-yl)-2-methylpropanenitrile 
• 1402389-14-3 2-[4-[5-amino-6-[3-[4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]isoxazol-5-yl]pyrazin-2-yl]pyridin-2-yl]-2-methylpropanenitrile 

Relevant articles and documents

PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula (I) or (II) wherein the variables are as defined herein.

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, a

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, a

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The invention relates to the compound 5-(4-isopropylsulfonylphenyl) -3-[3-[4-[(3R)-morpholin-3-yl]phenyl]isoxazol-5-yl]pyrazine-2-amine and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of ATR kinase.

AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I): wherein the variables are as defined herein.

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I wherein the variables are as defined herein.